322 related articles for article (PubMed ID: 15913972)
21. Use of human reconstituted epidermis Episkin for assessment of weak phototoxic potential of chemical compounds.
Portes P; Pygmalion MJ; Popovic E; Cottin M; Mariani M
Photodermatol Photoimmunol Photomed; 2002 Apr; 18(2):96-102. PubMed ID: 12147043
[TBL] [Abstract][Full Text] [Related]
22. The EpiSkin phototoxicity assay (EPA): development of an in vitro tiered strategy using 17 reference chemicals to predict phototoxic potency.
Lelièvre D; Justine P; Christiaens F; Bonaventure N; Coutet J; Marrot L; Cotovio J
Toxicol In Vitro; 2007 Sep; 21(6):977-95. PubMed ID: 17604947
[TBL] [Abstract][Full Text] [Related]
23. Intralaboratory and interlaboratory evaluation of the EpiDerm 3D human reconstructed skin micronucleus (RSMN) assay.
Hu T; Kaluzhny Y; Mun GC; Barnett B; Karetsky V; Wilt N; Klausner M; Curren RD; Aardema MJ
Mutat Res; 2009 Mar; 673(2):100-8. PubMed ID: 19167513
[TBL] [Abstract][Full Text] [Related]
24. In vitro skin irritation testing: Improving the sensitivity of the EpiDerm skin irritation test protocol.
Kandárová H; Hayden P; Klausner M; Kubilus J; Kearney P; Sheasgreen J
Altern Lab Anim; 2009 Dec; 37(6):671-89. PubMed ID: 20105002
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the phototoxic potential of compounds and finished topical products using a human reconstructed epidermis.
Medina J; Elsaesser C; Picarles V; Grenet O; Kolopp M; Chibout SD; de Brugerolle de Fraissinette A
In Vitr Mol Toxicol; 2001; 14(3):157-68. PubMed ID: 11846989
[TBL] [Abstract][Full Text] [Related]
26. Permeability of the reconstructed human epidermis model Episkin in comparison to various human skin preparations.
Netzlaff F; Kaca M; Bock U; Haltner-Ukomadu E; Meiers P; Lehr CM; Schaefer UF
Eur J Pharm Biopharm; 2007 Apr; 66(1):127-34. PubMed ID: 17029766
[TBL] [Abstract][Full Text] [Related]
27. The EpiDerm test protocol for the upcoming ECVAM validation study on in vitro skin irritation tests--an assessment of the performance of the optimised test.
Kandárová H; Liebsch M; Gerner I; Schmidt E; Genschow E; Traue D; Spielmann H
Altern Lab Anim; 2005 Aug; 33(4):351-67. PubMed ID: 16185104
[TBL] [Abstract][Full Text] [Related]
28. Further development of the EpiDerm 3D reconstructed human skin micronucleus (RSMN) assay.
Mun GC; Aardema MJ; Hu T; Barnett B; Kaluzhny Y; Klausner M; Karetsky V; Dahl EL; Curren RD
Mutat Res; 2009 Mar; 673(2):92-9. PubMed ID: 19167515
[TBL] [Abstract][Full Text] [Related]
29. A feasibility study developing an integrated testing strategy assessing skin irritation potential of chemicals.
Hoffmann S; Saliner AG; Patlewicz G; Eskes C; Zuang V; Worth AP
Toxicol Lett; 2008 Jul; 180(1):9-20. PubMed ID: 18585875
[TBL] [Abstract][Full Text] [Related]
30. A catch-up validation study of an in vitro skin irritation test method using reconstructed human epidermis LabCyte EPI-MODEL24.
Kojima H; Katoh M; Shinoda S; Hagiwara S; Suzuki T; Izumi R; Yamaguchi Y; Nakamura M; Kasahawa T; Shibai A
J Appl Toxicol; 2014 Jul; 34(7):766-74. PubMed ID: 24122860
[TBL] [Abstract][Full Text] [Related]
31. Xenobiotic metabolism gene expression in the EpiDermin vitro 3D human epidermis model compared to human skin.
Hu T; Khambatta ZS; Hayden PJ; Bolmarcich J; Binder RL; Robinson MK; Carr GJ; Tiesman JP; Jarrold BB; Osborne R; Reichling TD; Nemeth ST; Aardema MJ
Toxicol In Vitro; 2010 Aug; 24(5):1450-63. PubMed ID: 20350595
[TBL] [Abstract][Full Text] [Related]
32. Characterization of reconstructed skin models.
Ponec M; Boelsma E; Gibbs S; Mommaas M
Skin Pharmacol Appl Skin Physiol; 2002; 15 Suppl 1():4-17. PubMed ID: 12476005
[TBL] [Abstract][Full Text] [Related]
33. Novel cytokine marker available for skin irritation testing of medical devices using reconstructed human epidermis models.
Kato R; Miyajima A; Komoriya K; Haishima Y
Toxicol In Vitro; 2020 Oct; 68():104919. PubMed ID: 32645342
[TBL] [Abstract][Full Text] [Related]
34. Reconstructed skin kits: reproducibility of cutaneous irritancy testing.
Faller C; Bracher M
Skin Pharmacol Appl Skin Physiol; 2002; 15 Suppl 1():74-91. PubMed ID: 12476011
[TBL] [Abstract][Full Text] [Related]
35. In vitro skin irritation: facts and future. State of the art review of mechanisms and models.
Welss T; Basketter DA; Schröder KR
Toxicol In Vitro; 2004 Jun; 18(3):231-43. PubMed ID: 15046769
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of fibrin-based dermal-epidermal organotypic cultures for in vitro skin corrosion and irritation testing of chemicals according to OECD TG 431 and 439.
Morales M; Pérez D; Correa L; Restrepo L
Toxicol In Vitro; 2016 Oct; 36():89-96. PubMed ID: 27448499
[TBL] [Abstract][Full Text] [Related]
37. A new alternative method for testing skin irritation using a human skin model: a pilot study.
Miles A; Berthet A; Hopf NB; Gilliet M; Raffoul W; Vernez D; Spring P
Toxicol In Vitro; 2014 Mar; 28(2):240-7. PubMed ID: 24211334
[TBL] [Abstract][Full Text] [Related]
38. Sub-categorisation of skin corrosive chemicals by the EpiSkin™ reconstructed human epidermis skin corrosion test method according to UN GHS: revision of OECD Test Guideline 431.
Alépée N; Grandidier MH; Cotovio J;
Toxicol In Vitro; 2014 Mar; 28(2):131-45. PubMed ID: 24211528
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of reconstructed skin model by Raman microspectroscopy: comparison with excised human skin.
Tfayli A; Piot O; Draux F; Pitre F; Manfait M
Biopolymers; 2007 Nov; 87(4):261-74. PubMed ID: 17763468
[TBL] [Abstract][Full Text] [Related]
40. An integrated testing strategy for in vitro skin corrosion and irritation assessment using SkinEthic™ Reconstructed Human Epidermis.
Alépée N; Grandidier MH; Tornier C; Cotovio J
Toxicol In Vitro; 2015 Oct; 29(7):1779-92. PubMed ID: 26187475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
